netFormulary NHS
Dorset
The Dorset Formulary has been developed in associations with
NHS Dorset Clinical Commissioning Group
Dorset County Hospital NHS Foundation Trust
Dorset Healthcare University NHS Foundation Trust
University Hospitals Dorset NHS Foundation Trust
 Search
 Formulary Chapter 8: Malignant disease and immunosuppression - Full Chapter
Notes:

Updated in accordance with CDF and NICE guidance May 2018. For latest CDF list click here.

Chapter Links...
 Details...
08.01.05  Expand sub section  Other antineoplastic drugs
Cytotoxic Drug Amsacrine
 Track Changes
Formulary
Red
 
 
Cytotoxic Drug Arsenic Trioxide (Trisenox®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

Commissioned by NHSE in line NICE TA526 recommendations.

 
Link  NICE TA526: Arsenic trioxide for treating acute promyelocytic leukaemia
 
Cytotoxic Drug Axicabtagene ciloleucelBlack Triangle (YESCARTA®)
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Red
High Cost Medicine
Cancer Drugs Fund
BlueTeq

Commissioned by CDF in line with CDF criteria and NICE TA559 at commissioned CAR-T treatment centres only.


Commissioned centres include:



  • University College London Hospital NHS Foundation Trust

  • King’s College Hospital NHS Foundation Trust

  • University Hospitals Bristol NHS Trust

 
Link  NICE TA559: Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies
 
Cytotoxic Drug Bexarotene (Targretin®)
View adult BNF View SPC online  Track Changes
Formulary
Red
When approved for an individual patient 
 
Cytotoxic Drug Bortezomib (Velcade®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England
BlueTeq

In accordance with NICE TA (TA129, TA228, TA311) or CDF policy.

 
Link  NICE TA129: Bortezomib monotherapy for relapsed multiple myeloma
Link  NICE TA228: Bortezomib and thalidomide for the first-line treatment of multiple myeloma
Link  NICE TA311: Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation
 
Cytotoxic Drug Carfilzomib (Kyprolis®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

Carfilzomib with dexamethasone is recommended as an option for treating multiple myeloma in adults who have had only 1 previous therapy in accordance with NICE TA657.

 
Link  NICE TA657: Carfilzomib for previously treated multiple myeloma
 
Cytotoxic Drug Crisantaspase
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
 
 
Cytotoxic Drug Eribulin (Halaven®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
BlueTeq

Commissioned in accordance with NICE TA423 and TA515.

 
Link  NICE TA423: Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens (replaces TA250)
Link  NICE TA515: Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen (not recommended)
 
Cytotoxic Drug Hydroxycarbamide
View adult BNF View SPC online  Track Changes
Formulary
Amber SCG
Hospital initiation. Use in accordance with local shared care guideline. 
Link  Shared care guideline hydroxycarbamide Jan 2020
 
Cytotoxic Drug IxazomibBlack Triangle (Ninlaro®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
BlueTeq

Commissioned by CDF in accordance with CDF policy and NICE TA505 for use in combination with lenalidomide and dexamethasone if the conditions of the managed access agreement are followed.

 
Link  NICE TA505: Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma
 
Cytotoxic Drug Liposomal Cytarabine-Daunorubicin (Vyxeos®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

Commissioned by NHSE in line with NICE TA552 for untreated, high risk, acute myeloid leukaemia.

 
Link  NICE TA552: Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemia
 
LorlatinibBlack Triangle (Lorviqua®)
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Red
High Cost Medicine
NHS England
BlueTeq

Commissioned by NHSE in accordance with NICE TA628.

 
Link  NICE TA 628: Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer
 
Cytotoxic Drug Lutetium (177Lu) oxodotreotideBlack Triangle (Lutathera®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
BlueTeq

Commissioned by CDF in line with CDF criteria and NICE TA539.

 
Link  TA539: Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours
 
Cytotoxic Drug Mitotane (Lysodren®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
 
 
Cytotoxic Drug NiraparibBlack Triangle (Zejula®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
BlueTeq

Commissioned by CDF in line with CDF criteria and NICE TA528.

Commissioned by the CDF in line with NICE TA673 for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy.

 
Link  NICE TA528: Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer
Link  NICE TA673: Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy
 
Cytotoxic Drug Olaparib (Lynparza®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England
BlueTeq

Commissioned by CDF in accordance with NICE TA598 for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy

Commissioned by CDF in accordance with NICE TA620 for 2nd line maintenance therapy following relapse.
- NOTE: Under CDF review imminently

Commissoned by NHS England from 28/02/2020 in accordance with NICE TA620 for 3rd line maintenance therapy following relapse (IFA in place until this date)

 
Link  Class 3 medicines recall: Specific batches of LynparzaTM¥(olaparib) 50mg capsules April 2018
Link  NICE TA598: Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy
Link  NICE TA620: Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer
 
Cytotoxic Drug Panobinostat (Farydak®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Commissioned by NHSE for treating multiple myeloma after at least 2 previous treatments in accordance with NICE TA380 
Link  NICE TA380: Panobinostat for treating multiple myeloma after at least 2 previous treatments
 
Cytotoxic Drug Pegaspargase (Oncaspar®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
In accordance with NICE guidance. 
Link  NICE TA408: Pegaspargase for treating acute lymphoblastic leukaemia
 
Cytotoxic Drug Pentostatin (Nipent® )
View adult BNF View SPC online  Track Changes
Formulary
Red
 
 
Cytotoxic Drug Procarbazine
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
 
 
Cytotoxic Drug Rucaparib (Rubraca®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
BlueTeq

Commissioned by CDF in line with CDF criteria and NICE TA611.

 
Link  NICE TA611: Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer
 
Cytotoxic Drug Talimogene laherparepvec (Imlygic®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
BlueTeq

In accordance with NICE guidance.

 
Link  NICE TA410: Talimogene laherparepvec for treating unresectable metastatic melanoma
 
Cytotoxic Drug TisagenlecleucelBlack Triangle (Kymriah®)
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Red
High Cost Medicine
Cancer Drugs Fund
BlueTeq

Commissioned by CDF in line with CDF criteria and NICE TA554 & TA567 at commissioned CAR-T treatment centres only.


Commissioned centres include:



  • University College London Hospital NHS Foundation Trust

  • King’s College Hospital NHS Foundation Trust

  • University Hospitals Bristol NHS Trust

 
Link  NICE TA554: Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years
Link  NICE TA567: Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma in adults after 2 or more systemic therapies
 
Cytotoxic Drug Trabectedin (Yondelis®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
Commissioned by NHS England in accordance with NICE guidance.  
Link  NICE TA 389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Link  NICE TA185: trabectedin for the treatment of advanced soft tissue sarcoma
 
Cytotoxic Drug Tretinoin
(ATRA, all trans retinoic acid)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
 
 
Cytotoxic Drug VenetoclaxBlack Triangle (Venclyxto®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England
BlueTeq

Commissioned by CDF in line with NICE TA487 and TA561 and CDF recommendations.

Commissioned by NHSE in combination with Obinutuzumab as an option for untreated CLL where:
  •  there is a 17p deletion or TP53 mutation, OR
  •  there is NO 17p deletion or TP53 mutation, but fludarabine plus cyclophosphamide and rituximab (FCR), or bendamustine plus rituximab (BR), is unsuitable

Commissioned within the CDF in combination with Obinutuzumab as an option for untreated CLL where:
  •  there is NO 17p deletion or TP53 mutation, and
  •  fludarabine plus cyclophosphamide and rituximab (FCR), or bendamustine plus rituximab (BR) is suitable

 
Link  NICE TA487: Venetoclax for treating chronic lymphocytic leukaemia
Link  NICE TA561: Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia
Link  NICE TA663: Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia
 
08.01.05  Expand sub section  CDK inhibitors
08.01.05  Expand sub section  Dacarbazine and Temozolomide
Cytotoxic Drug Dacarbazine
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
 
 
Cytotoxic Drug Temozolomide
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine

Commissioned in accordance with NICE TA23 and TA121.


Routinely commissioned as an adjuvant therapy in (Adult) patients with newly diagnosed anaplastic astrocytoma without 1p/19q codeletion following surgery and radiotherapy (from April 2020) as per NHSE Commissioning Statement SSC 2136.


Not routinely commissioned by NHS England for non-malignant endocrinology conditions. As per IFR approval.

 
Link  NICE TA121: Carmustin implants and temozolomide for newly diagnosed glioma
Link  NICE TA23: Temozolomide in recurrent malignant glioma (brain cancer)
 
08.01.05  Expand sub section  Platinum compounds
Cytotoxic Drug Carboplatin
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
 
Link  Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer (TA285)
Link  Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer
 
Cytotoxic Drug Cisplatin
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
 
Link  Pemetrexed maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small-cell lung cancer
 
Cytotoxic Drug Oxaliplatin
View adult BNF View SPC online  Track Changes
Formulary
Red
 
Link  Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy (TA307)
Link  Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer (TA212)
Link  NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin
 
08.01.05  Expand sub section  Protein kinase inhibitors to top
Cytotoxic Drug AbemaciclibBlack Triangle (Verzenios®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
BlueTeq

Commissioned by CDF in line with NICE TA563 and TA579 and CDF criteria.

 
Link  NICE TA563: Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
Link  NICE TA579: Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy
 
Cytotoxic Drug AcalabrutinibBlack Triangle (Calquence®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
BlueTeq

Commissioned within the CDF as an option for untreated chronic lymphocytic leukaemia (CLL) in adults, only if:
  •  they have a 17p deletion or TP53 mutation

Commissioned within the CDF as a second-line option for treating CLL in adults where:
  •  ibrutinib is their only suitable treatment option

Commissioning will transfer to NHSE 90 days following NICE publication

 
 
Cytotoxic Drug AfatinibBlack Triangle (Giotrif®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
NHS England

Commissioned by NHS England in line with NICE TA310.

 
Link  NICE TA310: Lung cancer (non small cell, EGFR mutation positive) - afatinib
 
Cytotoxic Drug AlectinibBlack Triangle (Alecensa®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

Commissioned by NHSE in line with NICE TA536 recommendations.

 
Link  NICE TA536: Alectinib for untreated ALK-positive advanced non-small-cell lung cancer
 
Cytotoxic Drug Axitinib (Inlyta®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
NHS England

Commissioned by NHS England in line with NICE TA333.

 
Link  NICE TA 333: Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment
 
Cytotoxic Drug BinimetinibBlack Triangle (Mektovi®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
BlueTeq

Commissioned by CDF in line with NICE TA562 and CDF criteria (in combination encorafenib).

 
Link  NICE TA562: Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma
 
Cytotoxic Drug BosutinibBlack Triangle (Bosulif®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

Commissioned by NHS England in line with NICE TA401.

 
Link  NICE TA401 Bosutinib for previously treated chronic myeloid leukaemia
 
Cytotoxic Drug BrigatinibBlack Triangle (Alunbrig®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

Commissioned by NHSE in line with NICE TA571 as monotherapy for the treatment of adult patients with ALK-positive advanced non-small cell lung cancer previously treated with crizotinib.

Commissioned by NHSE in line with NICE TA670 as an option for treating anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer (NSCLC) that has not been previously treated with an ALK inhibitor in adults.
  •  This indication is funded by CDF until 27th April 2021

 
Link  NICE TA571: Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib
Link  NICE TA670: Brigatinib for ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor
 
Cytotoxic Drug CabozantinibBlack Triangle (Cometriq®, Cabometyx®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

Cabometyx®:



  • Commissioned by NHSE in accordance with NICE TA463 and TA542 for the treatment of previously treated advanced renal cell carcinoma and untreated locally advanced or metastatic renal cell carcinoma respectively.

  • Patients initiated on the Named Patient Programme should remain on free of charge stock for the duration of their treatment.


Cometriq®:



  • Commissioned in accordance with NICE TA516 for the first line treatment of medullary thyroid cancer.

 
Link  NICE TA463: Cabozantinib for previously treated advanced renal cell carcinoma
Link  NICE TA516: Cabozantinib for treating medullary thyroid cancer
Link  NICE TA542: Cabozantinib for untreated advanced renal cell carcinoma
 
Cytotoxic Drug CeritinibBlack Triangle (Zykadia®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

Commissioned by NHS England in line with NICE TA395 and TA500.

 
Link  NICE TA395: Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer
Link  NICE TA500: Ceritinib for untreated ALK-positive non-small-cell lung cancer
 
Cytotoxic Drug CrizotinibBlack Triangle (Xalkori®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England
BlueTeq

Commissioned by CDF in line with CDF criteria and NICE TA529 and NHS England in line with NICE TA406 and TA422.

 
Link  NICE TA406: Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
Link  NICE TA422: Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
Link  NICE TA529: Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer
 
Cytotoxic Drug DabrafenibBlack Triangle (Tafinlar®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
NHS England

Commissioned by NHS England in line with NICE TA321, TA396 and TA544.


BlueTeq TA396 and TA544 require BlueTeq prior approval.

 
Link  NICE TA:321: Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma
Link  NICE TA396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
Link  NICE TA544: Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma
 
Cytotoxic Drug Dacomitinib (Vizimpro®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

In accordance with NICE TA595

 
Link  NICE TA595: Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer
 
Cytotoxic Drug Dasatinib (Sprycel®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
BlueTeq

Commissioned by NHS England in line with NICE TA425 and TA426.

 
Link  NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Link  NICE TA426: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
 
Cytotoxic Drug EncorafenibBlack Triangle (Braftovi®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England
BlueTeq

Commissioned by CDF in line with NICE TA562 and CDF criteria (in combination binimetinib).

Commissioned by NHSE in combination with Cetuximab as an option for treating BRAF V600E mutation-positive metastatic colorectal cancer in adults who have had previous systemic treatment in line with NICE TA668.
  •  NOTE: Interim funding is via the CDF until April 6th 2021

 

 
Link  NICE TA562: Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma
Link  NICE TA668: Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer
 
Cytotoxic Drug EntrectinibBlack Triangle (Rozlytrek®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England
BlueTeq

Commissioned by NHSE in line with NICE TA643 for treating ROS1-positive advanced non-small-cell lung cancer (NSCLC) in adults who have not had ROS1 inhibitors.

Commissioned via the Cancer Drugs Fund (CDF) in line with NICE TA644 for treating neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumours in adults and children 12 years and older if:
   • the disease is locally advanced or metastatic or surgery could cause severe health problems and
   • they have not had an NTRK-inhibitor before and
   • they have no satisfactory treatment options.

 
Link  NICE TA643: Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer
Link  NICE TA644: Entrectinib for treating NTRK fusion-positive solid tumours
 
Cytotoxic Drug Erlotinib (Tarceva®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
Commissioned by NHS England for cancer, policy in progress. See NICE TA162 and TA374. 
Link  NICE TA258: Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer
Link  NICE374: Erlotinib and Gefitinib for the treatment of non-small-cell lung cancer that has progressed after prior chemotherapy (previously TA162)
Link  NICE TA227: Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer (not recommended)
 
Cytotoxic Drug Everolimus (Afinitor®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
BlueTeq

Commissioned by NHS England in line with NICE TA recommendations.

 
Link  NICE TA421: Everolimus with exemestane for treating advanced breast cancer after endocrine therapy
Link  NICE TA432: Everolimus for advanced renal cell carcinoma after previous treatment
Link  NICE TA449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
Link  NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma
 
Cytotoxic Drug Gefitinib (Iressa®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
Commissioned by NHS England in line with TA192. 
Link  NICE TA192: gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell-lung cancer
Link  NICE TA374: Gefitinib and erlotinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy (previously TA175) (not recommended)
 
Cytotoxic Drug GilteritinibBlack Triangle (Xospata®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

Commissioned by NHSE in line with NICE TA642 as monotherapy for treating relapsed or refractory FLT3‑mutation-positive acute myeloid leukaemia (AML) in adults.

Gilteritinib should not be given as maintenance therapy after a haematopoietic stem cell transplant.

 
Link  NICE TA642: Gilteritinib for treating relapsed or refractory acute myeloid leukaemia
 
Cytotoxic Drug Ibrutinib (Imbruvica® )
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England
BlueTeq

In accordance with CDF policy and NICE TA429, TA491 and TA502.

 
Link  NICE TA429:Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation
Link  NICE TA491: Ibrutinib for treating Waldenstrom’s macroglobulinaemia
Link  NICE TA502: Ibrutinib for treating relapsed or refractory mantle cell lymphoma
 
Cytotoxic Drug IdelalisibBlack Triangle (Zydelig® )
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
NHS England

Commissioned in accordance with NICE TA359.


 

 
Link  NICE TA 359: Idelalisib for treating chronic lymphocytic leukaemia
Link  NICE TA 469: Idelalisib with ofatumumab for treating chronic lymphocytic leukaemia (terminated appraisal)
 
Cytotoxic Drug Imatinib (Generic, Glivec®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
NHS England

For haematology indications use generic drug, for gastrointestinal stromal tumours use Glivec® brand.

 
Link  NICE TA70: guidance on the use of imatinib for chronic myeloid leukaemia
Link  NICE TA209: Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours
Link  NICE TA326: Imatinib for the adjuvant treatment of gastrointestinal stromal tumours (Previously NICETA196)
Link  NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Link  NICE TA426: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Link  NICE TA86: Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours
 
Cytotoxic Drug LarotrectinibBlack Triangle (Vitrakvi®)
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Red
High Cost Medicine
Cancer Drugs Fund
BlueTeq

Commissioned in line with CDF criteria and conditions of the managed access agreement in accordance with the recommendations in NICE TA630 for treating NTRK fusion-positive solid tumours.

 
Link  NICE TA630: Larotrectinib for treating NTRK fusion-positive solid tumours
 
Cytotoxic Drug LenvatinibBlack Triangle (Kisplyx®, Lenvima®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

Kisplyx®:



  • Commissioned by NHSE in accordance with NICE TA498 for the treatment of previously treated renal cell carcinoma in combination with everolimus.


Lenvima®:



  • Commissioned by NHSE in accordance with NICE TA535 for the treatment of differentiated thyroid cancer after radioactive iodine.

  • Commissioned by NHSE in accordance with NICE TA551 for first line treatment of Child Pugh A locally advanced or metastatic hepatocellular carcinoma.

 
Link  NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma
Link  NICE TA535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine
Link  NICE TA551: Lenvatinib for untreated advanced hepatocellular carcinoma
 
MidostaurinBlack Triangle (Rydapt®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

Commissioned by NHSE in line with NICE TA523 recommendations.

 
Link  NICE TA523: Midostaurin for untreated acute myeloid leukaemia
 
Neratinib (Nerlynx®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

Commissioned by NHSE in line with the recommendations in NICE TA612.

 
Link  NICE TA612: Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab
 
Cytotoxic Drug Nilotinib (Tasigna®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
BlueTeq

Commissioned by NHS England in line with NICE TA241 and TA251.

 
Link  NICE TA241: Dasatinib, nilotinib and high dose imatinib for CML
Link  NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Link  NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
 
Cytotoxic Drug Nintedanib Black Triangle (Vargatef®, Ofev®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
NHS England

Vargatef®:



  • Commissioned by NHS England in line with NICE TA347 for non-small-cell lung cancer.


Restricted Item Ofev®: 



  • Commissioned by NHS England in line with NICE TA379 for idiopathic pulmonary fibrosis via specialist centres only.

 
Link  NICE TA 347: Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer
Link  NICE TA379: Nintedanib for treating idiopathic pulmonary fibrosis
 
Cytotoxic Drug OsimertinibBlack Triangle (Tagrisso®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

Commissioned by NHSE for treating EGFR T790M mutation-positive advanced or metastatic non-small-cell lung cancer (NSCLC) in adults in accordance with NICE TA653, only if their disease has progressed after first-line treatment with an EGFR tyrosine kinase inhibitor.

Commissioned by NHSE for untreated EGFR mutation-positive locally advanced or metastatic non-small-cell lung cancer (NSCLC) in adults in accordance with NICE TA654.

 
Link  NICE TA653: Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer
Link  NICE TA654: Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer
 
Cytotoxic Drug PalbociclibBlack Triangle (IBRANCE®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England
BlueTeq

Commissioned in accordance with NICE TA495 for the treatment of previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer.


Patients inititated on the free of charge patient access programme should continue on free of charge treatment so long as they derive benefit.


Commissioned by CDF in line with NICE TA619 for treating hormone receptor-positive, HER2-negative, advanced breast cancer in combination with Fulvestrant.

 
Link  NICE TA495: Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
Link  NICE TA619: Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer
 
Cytotoxic Drug Pazopanib (Votrient®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
Commissioned by NHS England as per NICE TA215. 
Link  NICE TA215: pazopanib for the first line treatment of advanced renal cell carcinoma
 
PemigatinibBlack Triangle (Pemazyre®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
BlueTeq

Available under EAMS for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that is relapsed or refractory after at least one line of systemic therapy

 
 
Cytotoxic Drug PonatinibBlack Triangle (Iclusig®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

Commissioned by NHS England in line with NICE TA451.

 
Link  DSU vol 8, iss 4, Nov 2014: S2. Ponatinib (Iclusig): risk of vascular occlusive events
Link  NICE TA451: Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia
 
Cytotoxic Drug RegorafenibBlack Triangle (Stivarga® )
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

Commissioned by NHS England in line with NICE TA488 and TA555.

 
Link  NICE TA488: Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours
Link  NICE TA555: Regorafenib for previously treated advanced hepatocellular carcinoma
 
Cytotoxic Drug RibociclibBlack Triangle (Kisqali®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England
BlueTeq

Commissioned in accordance with NICE TA496 for the treatment of previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer.

Commissioned by the CDF in accordance with NICE TA687 for treating hormone receptor-positive, (HER2)-negative, locally advanced or metastatic breast cancer in adults  
- This indication will transition to NHSE on 29th June 2021

 
Link  NICE TA496: Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
Link  NICE TA687: Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy
 
Cytotoxic Drug Ruxolitinib (Jakavi®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

Commissioned by NHS England in line with NICE TA386.
BlueTeq is required for this indication from 16/12/2020

 

 
Link  NICE TA386: Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis
 
Cytotoxic Drug Sorafenib (Nexavar®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England
BlueTeq

Commissioned by NHS England in line with NICE TA474 and by CDF as per NICE TA535 and CDF policy.

 
Link  NICE TA474: Sorafenib for treating advanced hepatocellular carcinoma
Link  NICE TA535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine
 
Cytotoxic Drug Sunitinib (Sutent®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine

For use in line with NICE TA169, TA179 and TA449.


BlueTeq Blueteq prior approval required for the treatment of unresectable or metastatic neuroendocrine tumours of pancreatic origin with disease progression (TA449).

 
Link  NICE TA169: Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma
Link  NICE TA179: Sunitinib for the treatment of gastrointestinal stromal tumours
Link  NICE TA449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
Link  NICE TA178: Renal cell carcinoma (2nd line - not recommended)
 
Cytotoxic Drug TivozanibBlack Triangle (Fotivda®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

Commissioned by NHSE in accordance with NICE TA512.

 
Link  NICE TA512: Tivozanib for treating advanced renal cell carcinoma
 
Cytotoxic Drug TrametinibBlack Triangle (Mekinist®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England
BlueTeq

Commissioned by NHS England in line with NICE TA396.


Commissioned by |CDF in line with CDF criteria and NICE TA544.

 
Link  NICE TA396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
Link  NICE TA544: Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma
 
Cytotoxic Drug Vemurafenib (Zelboraf®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
Commissioned by NHS England in line with NICE TA269. 
Link  NICE TA269: vemurafenib for treating locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma
 
08.01.05  Expand sub section  Taxanes
Cytotoxic Drug Cabazitaxel (Jevtana®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
BlueTeq

Commissioned in accordance with NICE guidance.

 
Link  NICE TA391 Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel
 
Cytotoxic Drug Docetaxel
View adult BNF View SPC online  Track Changes
Formulary
Red
 
Link  NICE TA101: Prostate cancer (hormone-refractory) - docetaxel
Link  NICE TA109: Breast cancer (early) - docetaxel
 
Cytotoxic Drug Paclitaxel
View adult BNF View SPC online  Track Changes
Formulary
Red
 
Link  NICE TA55: Guidance on the use of paclitaxel in the treatment of ovarian cancer
Link  NICE TA108: Paclitaxel for the adjuvant treatment of early node-positive breast cancer
Link  NICE TA284: Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer
Link  NICE TA389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
 
Cytotoxic Drug Paclitaxel - Albumin Bound Formulation (Nab-paclitaxel) (Abraxane®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

Commissioned by NHS England in line with NICE TA476 in combination with gemcitabine for untreated metastatic pancreatic cancer.

 
Link  NICE TA476: Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer
 
08.01.05  Expand sub section  Topoisomerase I inhibitors
Cytotoxic Drug Irinotecan Hydrochloride
View adult BNF View SPC online  Track Changes
Formulary
Red
 
 
Cytotoxic Drug Topotecan
View adult BNF View SPC online  Track Changes
Formulary
Red

Commissioned by NHS England in line with NICE guidance.

 
Link  NICE TA183: topotecan for the treatment of recurrent and stage IVB cervical cancer
Link  NICE TA184: topotecan for the treatment of relapsed small-cell lung cancer
Link  NICE TA389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
 
08.01.05  Expand sub section  Monoclonal antibodies
Cytotoxic Drug AtezolizumabBlack Triangle (Tecentriq®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England
BlueTeq

Commissioned by CDF in line with CDF criteria and NICE TA492 recommendations at a dose of 1200mg every 3 weeks (Specialist Sevices Circular 2096 Dec 19). Other licensed dose schedules are not funded. 

 

Commissioned by NHSE in line with NICE TA520,TA525 and and TA584 recommendations. For NICE TA 520 and 525 the dose must be 1200mg every 3 weeks (Specialist Sevices Circular 2096 Dec 19). Other licensed dose schedules are not funded.  

 

Use in combination with bevacizumab, paclitaxel and carboplatin, for the treatment of adult patients with EGFR activating mutations or ALK positive tumour mutations metastatic non-squamous non-small cell lung cancer (NSCLC) after failure of appropriate targeted therapies via MHRA Early Access to Medicines Scheme (EAMS). For eligible patients, clinicians can request an application form for registration with Roche by sending an email to welwyn.atezolizumabEAMS@roche.com. Off-label indication.

 

Use in combination with nab-paclitaxel for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumours have PD-L1 expression >1% and who have not received prior chemotherapy for metastatic disease, as per NICE TA639.
   • Patients previously started for this indication via the MHRA Early Access to Medicines Scheme (EAMS) who do not meet the new criteria should continue to receive the drug from the manufacturer.

 

Use in combination with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer in adults with an ECOG score of 0 or 1, as per NICE TA638.
   • Patients previously started for this indication via the MHRA Early Access to Medicines Scheme (EAMS) who do not meet the new criteria should continue to receive the drug from the manufacturer.

Atezolizumab plus Bevacizumab is commissioned by NHSE as an option for treating advanced or unresectable hepatocellular carcinoma (HCC) in adults who have not had previous systemic treatment in line with NICE TA666, only if:
  •  they have Child-Pugh grade A liver impairment and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

Note (July 2018): The European Medicines Agency restricted the use of atezolizumab for untreated urothelial carcinoma. It should now only be used in adults with high levels of PD-L1. 

 
Link  NICE TA492: Atezolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (only in adults with high levels of PD-L1)
Link  NICE TA520: Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy
Link  NICE TA525: Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
Link  NICE TA584:Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer
Link  NICE TA638: Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer
Link  NICE TA639:Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer
Link  NICE TA666: Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma
 
Cytotoxic Drug AvelumabBlack Triangle (Bavencio®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England
BlueTeq

Commissioned by NHSE for the treatment of previously treated (with systemic cytotoxic chemotherapy) metastatic Merkel cell carcinoma in line with NICE TA517.


Available via CDF managed access agreement for the treatment of previously untreated (with systemic therapy) metastatic Merkel cell carcinoma - see link below.


Commissioned by the CDF in combination with Axitinib for untreated advanced renal cell carcinoma in adults as per NICE TA645 and NHSE commissioning statement SSC 2170.


Available via an EAMS scheme for the first-line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) whose disease has not progressed with first-line platinum-based induction chemotherapy.

 
Link  Managed Access Agreement: Avelumab for treating metastatic Merkel cell carcinoma
Link  NICE TA517: Avelumab for treating metastatic Merkel cell carcinoma
Link  NICE TA645: Avelumab with axitinib for untreated advanced renal cell carcinoma
 
Cytotoxic Drug Bevacizumab (Avastin®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
BlueTeq

Red 


For use in line with CDF criteria.

Restricted Item Commissioned by NHS England for neurofibromatosis by NHS England as per national protocol (see NF2 service specification) at specialist centres only.


 


Black 


Not recommended as per NICE TA560 with carboplatin, gemcitabine and paclitaxel for treating the first occurence of platinum-sensitive advanced ovarian cancer.

 
Link  NICE TA 560: Bevacizumab with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer (terminated appraisal)
 
Cytotoxic Drug Brentuximab vedotinBlack Triangle (Adcetris®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

Commissioned by NHSE in line with NICE TA478, TA524 and TA577 recommendations.

Commissioned by NHSE in line with NICE TA641 in combination with Cyclophosphamide, Doxorubicin and Prednisone (CHP) for untreated systemic anaplastic large cell lymphoma in adults.

 
Link  NICE TA478: Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma
Link  NICE TA524: Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma
Link  NICE TA577: Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma
Link  NICE TA641: Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma
 
Cemiplimab (Libtayo®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
Cancer Drugs Fund
BlueTeq

Commissioned in accordance with CDF policy and NICE TA592.

 
Link  NICE TA592: Cemiplimab for treating metastatic or locally advanced cutaneous squamous cell carcinoma
 
Cytotoxic Drug Cetuximab (Erbitux®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

For use in line with NICE TA recommendations.

 
Link  NICE TA118: Colorectal cancer (metastatic) - bevacizumab & cetuximab
Link  NICE TA145: Head and neck cancer - cetuximab
Link  NICE TA242: TA242 Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review)
Link  NICE TA439:Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
Link  NICE TA473: Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck
 
DaratumumabBlack Triangle (DARZALEX® )
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
BlueTeq

Commissioned by CDF for use as monotherapy in line with NICE TA510 and CDF criteria.


Commissioned by CDF for use in combination with bortezomib and dexamethasone in line with NICE TA573 and CDF criteria.

 
Link  NICE TA510: Daratumumab monotherapy for treating relapsed and refractory multiple myeloma
Link  NICE TA573: Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma
Link  NICE TA454: Daratumumab with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)
Link  NICE TA634: Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma (terminated appraisal)
 
DinumtuximabBlack Triangle (Qarziba®)
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Red
High Cost Medicine
NHS England
BlueTeq

Commissioned by NHSE in line with NICE TA538 at or under shared care with a neuro-oncology centre.

 
Link  NICE TA538: Dinutuximab beta for treating neuroblastoma
 
DurvalumabBlack Triangle (Imfinzi®)
View adult BNF View SPC online  Track Changes
Formulary
Red
Cancer Drugs Fund
BlueTeq

 Commissioned by CDF in line with NICE TA578 and CDF criteria.

 
Link  NICE TA578: Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation
 
Cytotoxic Drug Gemtuzumab ozogamicinBlack Triangle (MYLOTARG®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

Commissioned by NHSE in line with NICE TA545.

 
Link  NICE TA545: Gemtuzumab ozogamicin for untreated acute myeloid leukaemia
 
Cytotoxic Drug Inotuzumab ozogamicinBlack Triangle (BESPONSA®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

Commissioned by NHSE in line with NICE TA541.

 
Link  NICE TA541: Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia
 
Cytotoxic Drug Ipilimumab (YERVOY ®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England

Commissioned by NHSE in line with NICE TA268, TA319 and TA400 recommendations.


BlueTeq Commissioned by CDF in combination with nivolumab in line wth CDF criteria. 

 
Link  NICE TA268: Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma
Link  NICE TA319: Ipilimumab for untreated advanced (unresectable or metastatic) melanoma
Link  NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma
 
IsatuximabBlack Triangle (Sarclisa®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
BlueTeq

Commissioned within the CDF in combination with pomalidomide and dexamethasone as a 4th line option for treating relapsed and refractory multiple myeloma as per NICE TA 658.

 
Link  NICE TA 658: Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma
 
Cytotoxic Drug NivolumabBlack Triangle (Opdivo®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England
BlueTeq

Commissioned by NHSE for:
- Melanoma, in line with NICE TA384 and TA400
- Renal Cell Carcinoma, in line with NICE TA417
- Hodgkin's Lymphoma, in line with NICE TA462

Commissioned by the CDF for:
- Melanoma, in line with NICE TA684 (NOTE: switching to NHSE commissioning on 15th June 2021)
- Renal Cell Carcinoma, in line with NICE TA581
- Lung Cancer, in line with NICE TA484 or TA655
- Head & Neck Cancer, in line with NICE TA490

Via Early Access to Medicines Scheme (EAMS) for:
- Mesothelioma: previously untreated, unresectable malignant disease of pleural origin, in combination with Ipilimumab

 
Link  NICE TA384: Nivolumab for treating advanced (unresectable or metastatic) melanoma
Link  NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma
Link  NICE TA417: Nivolumab for previously treated advanced renal cell carcinoma
Link  NICE TA462: Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma
Link  NICE TA484: Nivolumab for previously treated non-squamous non-small-cell lung cancer
Link  NICE TA490: Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy
Link  NICE TA558: Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease
Link  NICE TA581: Nivolumab with ipilimumab for untreated advanced renal cell carcinoma
Link  NICE TA655:Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy
Link  NICE TA684: Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease
 
Cytotoxic Drug Panitumumab (Vectibix®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

Commissioned by NHSE in line with NICE TA439.

 
Link  NICE TA439:Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
Link  NICE TA240: Panitumumab in combination with chemotherapy for the treatment of metastatic colorectal cancer (terminated appraisal)
Link  NICE TA242: Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy (not recommended)
 
Cytotoxic Drug PembrolizumabBlack Triangle (Keytruda®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England
BlueTeq

Commissioned by NHSE for:
- Melanoma, in line with NICE TA357, TA366
- Lung Cancer, in line with NICE TA428, TA531
- Head & Neck Cancer, in line with NICE TA661

Commissioned by the CDF for:
- Melanoma, in line with NICE TA553
- Lung Cancer, in line with NICE TA600, TA683 (switching to NHSE on 14/4/21)
- Urothelial Carcinoma, in line with NICE TA519 (decommissioning on 28/4/21), TA522 (decommissioning on 14/4/21)
- Hodgkin's Lymphoma, in line with NICE TA540

All commissioned indications require a BlueTeq form

 
Link  NICE TA 357: Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab
Link  NICE TA 366: Pembrolizumab for advanced melanoma not previously treated with ipilimumab
Link  NICE TA428: Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy
Link  NICE TA519: Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
Link  NICE TA522: Pembrolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable
Link  NICE TA531: Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer
Link  NICE TA540: Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma
Link  NICE TA553: Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence
Link  NICE TA600: Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer
Link  NICE TA661: Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma
Link  NICE TA683: Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer
 
Cytotoxic Drug Pertuzumab (Perjeta®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

Commissioned by NHSE in line with NICE TA424, TA509 and TA569.

PHESGO® (Pertuzumab/Trastuzumab) subcutaneous injection
NHSE have advised as of 10/2/21 that the combination subcutaneous PHESGO product may be used in place of the separate IV preparations for the existing commissioned indications (NICE TA424,509 and 569)

 
Link  NICE TA424: Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer
Link  NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer
Link  NICE TA569: Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer
 
Cytotoxic Drug Polatuzumab vedotinBlack Triangle (Polivy®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

Commissioned via NHSE in combination with rituximab and bendamustine as an option for treating relapsed or refractory diffuse large B-cell lymphoma in adults who cannot have a haematopoietic stem cell transplant as per NICE TA649.

 
Link  NICE TA649: Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma
 
Cytotoxic Drug Trastuzumab (Ontruzant®, Herceptin®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
NHS England

Biosimilar trastuzumab should be used for intravenous treatment where possible.

 
Link  NICE TA107: Breast cancer (early) - trastuzumab
Link  NICE TA208: Gastric cancer (HER2-positive metastatic) - trastuzumab
Link  NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
Link  NICE TA34: Breast cancer - trastuzumab
 
Cytotoxic Drug Trastuzumab emtansineBlack Triangle (Kadcyla®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

Commissioned by NHSE for treating HER2-positive advanced breast cancer after trastuzumab and a taxane, as per NICE TA458.


Commissioned by NHSE for adjuvant treatment of HER2-positive early breast cancer in adults who have residual invasive disease in the breast or lymph nodes after neoadjuvant taxane-based and HER2‑targeted therapy, as per NICE TA632.

 
Link  Kadcyla - Prevention of medication errors July 2017
Link  NICE TA458: Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane (replaces TA371)
Link  NICE TA632: Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer
 
 ....
 Non Formulary Items
Cytotoxic Drug  Afatinib  (Giotrif®)

View adult BNF View SPC online View childrens BNF Track Changes
Non Formulary
Black
Not recommended by NICE TA 444 for locally advanced or metastatic squamous non-small-cell lung cancer after platinum-based chemotherapy
Link  NICE TA 444 Afatinib for treating advanced squamous non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal)
Link  NICE TA 452: Ibrutinib for untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation (terminated appraisal)
Cytotoxic Drug  Alectinib

View adult BNF View SPC online View childrens BNF Track Changes
Non Formulary
Black
High Cost Medicine

Not recommended for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer in accordance with NICE TA438

Link  NICE TA438: Alectinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (terminated appraisal)
Cytotoxic Drug  Bortezomib  (Velcade®)

View adult BNF View SPC online View childrens BNF Track Changes
Non Formulary
Black

In accordance with NICE TA 453.

Link  NICE TA Bortezomib for treating multiple myeloma after second or subsequent relapse (terminated appraisal)
Cytotoxic Drug  Bosutinib Black Triangle  (Bosulif®)

View adult BNF View SPC online Track Changes
Non Formulary
Black
High Cost Medicine

Not recommended by NICE TA576 for untreated chronic myeloid leukaemia.

Link  NICE TA576: Bosutinib for untreated chronic myeloid leukaemia (terminated appraisal)
Cytotoxic Drug  Brentuximab vedotin  (Adcetris®)

View adult BNF View SPC online Track Changes
Non Formulary
Black
High Cost Medicine

 


Not commissioned for the treatmet of untreated advanced Hodgkin lyphoma in accordance with NICE TA594.

Link  NICE TA594: Brentuximab vedotin for untreated advanced Hodgkin lymphoma (terminated appraisal)
Cytotoxic Drug  Cabozantinib Black Triangle  (Cometriq®)

View adult BNF View SPC online Track Changes
Non Formulary
Black
High Cost Medicine
NHS England

Not recommended in accordance with NICE TA582

Link  NICE TA463: Cabozantinib for previously treated advanced renal cell carcinoma
Link  NICE TA516: Cabozantinib for treating medullary thyroid cancer
Link  NICE TA542: Cabozantinib for untreated advanced renal cell carcinoma
Cytotoxic Drug  Cobimetinib hemifumarate  (Cotellic®)

View adult BNF View SPC online View childrens BNF Track Changes
Non Formulary
Black
High Cost Medicine
Not recommended by NICE TA414 for treating unresectable or metastatic melanoma in adults with a BRAF V600 mutation.
Link  NICE TA582:Cabozantinib for previously treated advanced hepatocellular carcinoma (terminated appraisal)
Cytotoxic Drug  Dabrafenib Black Triangle  (Tafinlar®)

View adult BNF View SPC online Track Changes
Non Formulary
Black
High Cost Medicine

Not recommended with trametinib for treating advanced metastatic BRAF V600E mutation-positive non-small-cell lung cancer as per NICE TA564.

Link  NICE TA564: Dabrafenib with trametinib for treating advanced metastatic BRAF V600E mutation-positive non-small-cell lung cancer (terminated appraisal)
Daratumumab Black Triangle  (DARZALEX® )

View adult BNF View SPC online Track Changes
Non Formulary
Black
High Cost Medicine

 


Not recommended for use in combination with lenalidomide and dexamethasone for untreated, relapsed or refractory multiple myeloma as per NICE TA634 and TA454.

Link  NICE TA454: Daratumumab with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)
Link  NICE TA634: Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma (terminated appraisal)
Cytotoxic Drug  Elotuzumab  (Empliciti®)

View adult BNF View SPC online View childrens BNF Track Changes
Non Formulary
Black
High Cost Medicine
In accordance with NICE TA 434
Link  Elotuzumab for previously treated multiple myeloma
Cytotoxic Drug  Everolimus  (Votubia®)

View adult BNF View SPC online View childrens BNF Track Changes
Non Formulary
Black
High Cost Medicine
Commissioned by NHS England via specialist centres only for:
  • renal angiomyolipoma associated with tubular sclerosis
  • subependymal giantcell astrocytoma (SEGA) associated with tuberous sclerosis complex
  • Link  Clinical Commissioning Policy 16066/P: Everolimus for subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex
    Link  Clinical Commissioning Policy Statement B14X09: Everolimus for treatment of angiomyolipomas associated with tuberous sclerosis
    Cytotoxic Drug  Ibrutinib  (Imbruvica® )

    View adult BNF View SPC online Track Changes
    Non Formulary
    Black
    High Cost Medicine

    In accordance with NICE TA437, TA452 and T608.

    Link  NICE TA437: Ibrutinib with bendamustine and rituximab for treating relapsed or refractory chronic lymphocytic leukaemia after systemic therapy
    Link  NICE TA452: Ibrutinib for untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation (terminated appraisal)
    Link  NICE TA608: Ibrutinib with rituximab for treating Waldenstrom’s macroglobulinaemia (terminated appraisal)
    Cytotoxic Drug  Idelalisib Black Triangle  (Zydelig® )

    View adult BNF View SPC online Track Changes
    Non Formulary
    Black
    High Cost Medicine
    NHS England

    Not commissioned in combination with ofatumumab in accordance with as per NICE TA469 or for treating refractory follicular lymphoma as per NICE 604

    Link  NICE TA604: Idelalisib for treating refractory follicular lymphoma
    Link  NICE TA 469: Idelalisib with ofatumumab for treating chronic lymphocytic leukaemia (terminated appraisal)
    Cytotoxic Drug  Lapatinib  (Tyverb®)

    View adult BNF View SPC online View childrens BNF Track Changes
    Non Formulary
    Black
    High Cost Medicine
    Not recommomended by NICE
    Link  NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
    Necitumumab  (Portrazza®)

    View adult BNF View SPC online View childrens BNF Track Changes
    Non Formulary
    Black
    High Cost Medicine
    Not commissioned because not recommended by NICE.
    Link  NICE TA 411: Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer
    Cytotoxic Drug  Nivolumab Black Triangle  (Opdivo®)

    View adult BNF View SPC online View childrens BNF Track Changes
    Non Formulary
    Black
    High Cost Medicine

    Nivolumab is not recommended, within its marketing authorisation, for treating locally advanced unresectable or metastatic urothelial carcinoma in adults who have had platinum-containing therapy as per NICE TA530.

    Link  NICE TA530: Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy
    Cytotoxic Drug  Olaratumab Black Triangle  (Lartruvo®)

    View adult BNF View SPC online Track Changes
    Non Formulary
    Black
    High Cost Medicine
    Cancer Drugs Fund
    BlueTeq

    23/01/2019:


    Following the press release by the European Medicines Agency (see below), the CDF will not fund any new patients to start olaratumab in combination with doxorubicin for the treatment of advanced soft tissue sarcoma, while full results from the study are awaited.


    For patients currently being treated with olaratumab and appearing to benefit from it, they and their doctors should discuss the lack of survival benefit with the addition of olaratumab and decide as to whether to continue treatment with olaratumab or not.

    Link  EMA press release: No new patients should start treatment with Lartruvo after study shows cancer medicine does not prolong life
    Link  NICE TA465: Olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma
    Padeliporfin Black Triangle  (TOOKAD®)

    View SPC online Track Changes
    Non Formulary
    Black
    High Cost Medicine

    As per NICE TA546 padeliporfin is not recommended, within its marketing authorisation, for untreated, unilateral, low-risk prostate cancer in adults.

    Link  NICE TA546: Padeliporfin for untreated localised prostate cancer
    Cytotoxic Drug  Pegylated Irinotecan Hydrochloride  (Onivyde®)

    View adult BNF View SPC online View childrens BNF Track Changes
    Non Formulary
    Black
    In accordance with NICE TA 440
    Link  NICE TA440: Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine
    Cytotoxic Drug  Ramucirumab  (Cyramza®)

    View adult BNF View SPC online View childrens BNF Track Changes
    Non Formulary
    Black
    High Cost Medicine

    Not recommended by NICE TA403, TA609 and TA635

    Link  NICE TA 403: Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer
    Link  NICE TA609: Ramucirumab for treating unresectable hepatocellular carcinoma after sorafenib (terminated appraisal)
    Link  NICE TA635: Ramucirumab with erlotinib for untreated EGFR-positive metastatic non-small-cell lung cancer (terminated appraisal)
    Rilonacept

    View adult BNF View SPC online View childrens BNF Track Changes
    Non Formulary
    High Cost Medicine
    Not routinely commissioned by NHS England (for cryopyrin-associated periodic syndromes). As per IFR approval.
    Cytotoxic Drug  Sorafenib

    View adult BNF View SPC online View childrens BNF Track Changes
    Non Formulary
    Black

    Not recommended as first or second line for advanced/metastatic renal cell cancer (as in NICE TA178).


    Also not recommended in the treatment of advanced hepatocellular cancer with Child-Pugh gradeB liver impairment (NICE TA474).

    Cytotoxic Drug  Temsirolimus  (Torisel®)

    View adult BNF View SPC online View childrens BNF Track Changes
    Non Formulary
    Black
    High Cost Medicine
    NICE do not recommended temsirolimus as a first drug treatments for people with advanced and/or metastatic renal cell carcinoma.
    Link  NICE TA178: temsirolimus for first-line treatment of advanced and/or metastatic renal cell carcinoma (not recommended)
    Link  NICE TA207: Mantle cell lymphoma (relapsed) - temsirolimus (terminated appraisal)
    Cytotoxic Drug  Topotecan

    View adult BNF View SPC online View childrens BNF Track Changes
    Non Formulary
    Black
    Not recommended within its marketing authorisation for treating:
    - first recurrence of platinum‑sensitive ovarian cancer
    - recurrent platinum‑resistant or platinum‑refractory ovarian cancer -NICE TA 389


    Link  NICE TA 389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
    Cytotoxic Drug  Trametinib Black Triangle  (Mekinist®)

    View adult BNF View SPC online Track Changes
    Non Formulary
    Black
    High Cost Medicine

    Not recommended with dabrafenib for treating advanced metastatic BRAF V600E mutation-positive non-small-cell lung cancer as per NICE TA564.

    Link  NICE TA654: Dabrafenib with trametinib for treating advanced metastatic BRAF V600E mutation-positive non-small-cell lung cancer (terminated appraisal)
    Cytotoxic Drug  Vandetanib Black Triangle  (Caprelsa®)

    View adult BNF View SPC online Track Changes
    Non Formulary
    Black
    High Cost Medicine
    Cancer Drugs Fund

    In line with NICE TA550 from 11 February 2019 no new patients will be able to receive the drug for treating aggressive and symptomatic medullary thyroid cancer. However, existing patients, registered prior to this date and receiving the drug via CDF funding will continue to receive the drug funded by the CDF until they and their NHS clinician consider it appropriate to stop.

    Link  NICE TA550: Vandetanib for treating medullary thyroid cancer - not recommended
    Cytotoxic Drug  Vismodegib Black Triangle  (Erivedge®)

    View adult BNF View SPC online Track Changes
    Non Formulary
    Black
    High Cost Medicine

    Following the publication of the negative NICE TA489 on 22/11/2017 vismodegib was de-listed from the CDF on 22/01/2018. No longer routinely commissioned.

    Link  NICE TA489: Vismodegib for treating basal cell carcinoma (not recommended)
      
    Key
    note Notes
    Section Title Section Title (top level)
    Section Title Section Title (sub level)
    First Choice Item First Choice item
    Non Formulary Item Non Formulary section
    Restricted Drug
    Restricted Drug
    Unlicensed Drug
    Unlicensed
    Track Changes
    Display tracking information
    click to search medicines.org.uk
    Link to adult BNF
    click to search medicines.org.uk
    Link to children's BNF
    click to search medicines.org.uk
    Link to SPCs
    Cytotoxic Drug
    Cytotoxic Drug
    CD
    Controlled Drug
    High Cost Medicine
    High Cost Medicine
    Cancer Drugs Fund
    Cancer Drugs Fund
    NHSE
    NHS England
    Homecare
    Homecare
    CCG
    CCG

    Traffic Light Status Information

    Status Description

    Green

    May be initiated, stabilised and maintained in primary, secondary or tertiary care  

    Amber

    Amber drug - without shared care  

    Amber SCG

    Amber drug - with shared care guideline  

    Red

    For secondary or tertiary care initiation and long-term maintenance of prescribing  

    Black

    Not recommended  

    netFormulary